Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1520 of 5804
-
Tighter blood sugar targets during pregnancy: could they protect newborns?
Disease control Recruiting nowThis is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Spinal zaps and exercise may boost walking after injury
Symptom relief OngoingFor many people with spinal cord injury (SCI), the goal of walking is a high priority. There are many approaches available to restore walking function after SCI; however, these approaches often involve extensive rehabilitation training and access to facilities, qualified staff, a…
Phase: NA • Sponsor: Shepherd Center, Atlanta GA • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New Drug-Free program shows promise for easing anxiety in severe mental illness
Symptom relief CompletedFew alternatives to addictive medical treatment exists for persons with severe mental health problems (SMHP) and anxiety, often connected to high risk of suicide. Access to effective interventions that depart in individuals' needs to cope with anxiety in everyday life is crucial …
Phase: NA • Sponsor: Lund University • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Slovenian study aims to predict who benefits from melanoma immunotherapy
Knowledge-focused Recruiting nowThe purpose of this study is to evaluate the efficacy of immunotherapy in the first-line treatment of metastatic melanoma in Slovenia and to investigate the association between PD-L1 expression and treatment response. The study aims to determine the relationship between exosomal …
Phase: NA • Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Chemo-Free combo for lymphoma shows promise in early trial
Disease control TerminatedFor marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but does no…
Phase: PHASE2 • Sponsor: University of Ulm • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Spinal zaps show promise for stroke Survivors' gait
Symptom relief Recruiting nowThis study has two interventional components, the first is a cross-over design and the second is a randomized control trial. Both will evaluate the effectiveness of transcutaneous (non-invasive) spinal cord stimulation on gait and balance function for individuals with hemiplegia …
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Gut shield: probiotic and amino acid combo may stop cancer drug side effect
Prevention Recruiting nowThis open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The mai…
Phase: PHASE3 • Sponsor: Instituto Nacional de Cancerologia de Mexico • Aim: Prevention
Last updated Jun 27, 2026 12:05 UTC
-
Could a common steroid save lives in sepsis? new trial investigates
Disease control CompletedThe purpose of this study is to investigate the safety and efficacy of early administration of two different doses of dexamethasone in high risk septic patients.
Phase: PHASE1, PHASE2 • Sponsor: CHA University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Brain training targets voices in schizophrenia
Symptom relief Recruiting nowNeurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Phase: NA • Sponsor: Boston VA Research Institute, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 18:46 UTC
-
Could a common diabetes drug ease leg pain for millions?
Symptom relief Recruiting nowPeripheral arterial disease (PAD) affects over 20% of aged adults and is very common among Veterans due significant tobacco use. PAD is due to the progressive blockage of peripheral arteries, predominantly to the legs, and results in intermittent claudication (IC) or recurrent mu…
Phase: PHASE3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Could viagra help COPD patients catch their breath?
Symptom relief Recruiting nowChronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion. The mechanisms responsible for shortness of breath on exertion are well understood in moderate and severe CO…
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New pill shows promise in quieting MS brain lesions
Disease control OngoingThis is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated. Participants will be randomized to receive either fenebrutinib or placebo. This study …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Brain biotype may predict best antipsychotic drug
Disease control Recruiting nowThe CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 gro…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis is a Phase 2, single center, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic high grade neuroendocrine cervical cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug targets brain inflammation to slow Alzheimer's
Disease control CompletedThe goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, …
Phase: PHASE2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Can a pill make CAR T-Cells last longer?
Disease control OngoingWhile chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K in…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immune cells from cord blood aim to wipe out hidden colon cancer
Disease control CompletedA study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Amniotic fluid shots aim to heal stubborn leg wounds
Disease control Recruiting nowDL-VSU-201 is a randomized, double-blind, placebo-controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of …
Phase: PHASE2 • Sponsor: Merakris Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Exercise may soothe chemo nerve pain, trial hopes
Symptom relief OngoingThis phase II trial studies whether using exercise is better than the usual approach for treating chemotherapy-induced peripheral neuropathy (CIPN). CIPN occurs when chemotherapy damages the nerves communicating between the brain, spinal cord, and the rest of the body. The usual …
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New combo tackles Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count re…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC